- ≥99% by HPLC; lot-matched COA available
- Lot-matched certificate of analysis
- Ships next business day, tracked
AOD-9604
Modified hGH 176-191 fragment peptide for lipolysis research
- FormLyophilized powder, sealed glass vial with flip-off seal
- Mol. weight1815.08 g/mol
- Research areasAdipocyte lipolysis, lipogenesis inhibition, metabolic signaling independent of GH receptor
Supplied for laboratory research use only. Not for human or veterinary use, and not intended to diagnose, treat, cure or prevent any disease.
Overview
AOD-9604 is a 16-residue synthetic peptide derived from the C-terminal region of human growth hormone. It reproduces the hGH 177-191 fragment with an added N-terminal tyrosine and retains the intramolecular disulfide bridge between the two cysteine residues, which holds the fragment in the loop conformation associated with its reported activity. The segment was isolated because the lipolytic region of growth hormone appears to be structurally separable from the domains that drive receptor-mediated growth signaling.
Specifications
Identity
- CAS number
- 221231-10-3
- Molecular formula
- C78H123N23O23S2
- Molecular weight
- 1815.08 g/mol
- Amino acid sequence
- Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe
- Peptide class
- Growth hormone C-terminal fragment analog (hGH 176-191 series)
Supply & purity
- Form
- Lyophilized powder, sealed glass vial with flip-off seal
- Purity
- ≥99% by HPLC; lot-matched COA available
- Available sizes
- 5 mg, 10 mg
- Solubility
- Bacteriostatic water; sterile water and dilute acetic acid also reported
Handling & storage
- Storage (lyophilized)
- −20 °C, sealed and protected from light and moisture
- Storage (reconstituted)
- 2–8 °C, protected from light; use within the study window
Additional detail
- Disulfide bridge
- Cys7-Cys15, cyclized
- Research areas
- Adipocyte lipolysis, lipogenesis inhibition, metabolic signaling independent of GH receptor
Questions about AOD-9604
How is AOD-9604 different from HGH Fragment 176-191?
They share the same core C-terminal growth hormone segment, but AOD-9604 is the cyclized, tyrosine-modified version with a Cys7-Cys15 disulfide bridge. That difference shows up in the molecular formula and in reversed-phase retention, and laboratories often compare the two directly.
What purity and documentation are supplied?
Every lot is HPLC tested to at least 99% purity with identity confirmed by mass spectrometry, and a lot-matched certificate of analysis is available. The COA is tied to the vial number shipped so purity data traces to your material.
Why avoid reducing agents?
The disulfide bridge between Cys7 and Cys15 holds the fragment in its cyclic conformation. Reducing agents in a buffer will open that bridge and produce a linear species with different chromatographic and biological behavior, which confounds assay results.
How should it be stored?
Store the sealed lyophilized vial at −20 °C, protected from light and moisture. After reconstitution, refrigerate at 2–8 °C, protect from light and use within your documented study window. Prepare aliquots to avoid repeated freeze-thaw cycles.
Related
